GRFS - Grifols SA ADR logo

GRFS

Grifols SA ADR

Net income grew 100% of yearsRevenue grew 100% of years1Y
Compare GRFS Hold

Grifols develops, produces, and markets plasma-derived medicines and diagnostic solutions, primarily serving hospitals and life-science research sectors. Its offerings include hemoderivatives, diagnostic equipment, clinical nutrition, and healthcare solutions.

โš•๏ธ Healthcare NASDAQ Listed 2006 $ USD
$1,000 invested 1 year ago โ†’$765today

Score Overview

1 Year
Score
Net Growth17.19%
Net TrendGrew
Net Income Consistencyโ€”
Rev Growth2.81%
Rev TrendGrew
Revenue Consistencyโ€”
5 Years
Score7.4
Net Growth139.76%
Net Trend60%
Net Income Consistencyโ€”
Rev Growth50.62%
Rev TrendEvery year
Revenue Consistencyโ€”
10 Years
Score
Net Growth-17.04%
Net Trend50%
Net Income Consistency
Rev Growth83.48%
Rev Trend90%
Revenue Consistency
20 Years
Score6.4
Net Growth9x
Net Trend65%
Net Income Consistency
Rev Growth11x
Rev Trend95%
Revenue Consistency
All Time
Score
Net Growth9x
Net Trend65%
Net Income Consistency
Rev Growth11x
Rev Trend95%
Revenue Consistency

Explore the 2021 public Archive ranking โ†’

Where Grifols SA ADR has ranked, year by year

Measure
Fundamentals Window

Showing 5 years ranking history by HDB Score.

Reached the top 50 on HDB Score in 1 year, the longest run being 1 in a row โ€” but not in 2021.

  • GRFS

2012: 29.9% ยท 2021: 29.5% ยท free through 2021 ยท longest runs

Net Income x Stock Price

Historical Returns

Historical Returns
PeriodPriceReturn
Last Price2026-09-28
$ 7.41โ€”
1 Year2025-09-26
$ 9.69-23.53%
5 Years2021-09-28
$ 14.72-49.68%
10 Years2016-09-28
$ 13.94-46.85%

Prices are split & dividend adjusted. All values are reported in USD.

Fundamental Data

Year
2026$ 7.43B$ 452M$ 529M
2025$ 7.22B$ 386M$ 824M
2024$ 7.21B$ 156M$ 1.00B
2023$ 6.59B$ 42M$ 646M
2022$ 6.06B$ 185M$ 580M
2021$ 4.93B$ 188M$ 2.68B
2020$ 5.34B$ 618M$ 590M
2019$ 5.09B$ 625M$ 2.75B
2018$ 4.48B$ 596M$ 1.03B
2017$ 4.31B$ 662M$ 886M
2016$ 4.04B$ 545M$ 895M
2015$ 3.93B$ 532M$ 1.14B
2014$ 3.35B$ 470M$ 1.07B
2013$ 2.74B$ 345M$ 708M
2012$ 2.62B$ 256M$ 473M
2011$ 1.79B$ 50M$ 357M
2010$ 990M$ 115M$ 252M
2009$ 913M$ 147M$ 257M
2008$ 814M$ 121M$ 13M
2007$ 703M$ 87M$ 12M
IPO2006$ 648M$ 45M$ 33M
GRFS - Grifols SA ADR logo

Grifols SA ADR fundamental performance

Between 2020 and 2025, revenue grew from $ 5.34B to $ 7.22B and net income declined from $ 618M to $ 386M. Revenue increased in every one of those 5 years; net income in 3.

Between 2006 and 2025, revenue grew from $ 648M to $ 7.22B and net income grew from $ 45M to $ 386M. Revenue increased in 95% of the years measured; net income in 65%.

Grifols SA ADR currently holds a 20-year HDB Score of 6.4 out of 10. How the HDB Score is calculated.

Membership

Continue GRFSโ€™s history

The public Archive runs through 2021. Membership adds recent and current rankings.

  • Recent and current rankings across 3,816 companies
  • Compare companies with the latest data
  • Track your research shortlist in a portfolio

$99 / year

$149/year ยท Founding price

Continue with Membership

30-day money-back guarantee.

Explore other companies